Robert Schotzinger, M.D., Ph.D., President & CEO and Director

Dr. Schotzinger brings nearly 20 years of research, development and management experience to Viamet, where he has raised significant private equity, completed three major partnerships and moved Viamet from a seed-stage company to a clinical-stage company. Prior to joining Viamet, Dr. Schotzinger was President and CEO of BioStratum Inc., a privately-held biotechnology company, where he was responsible for moving the company's lead drug candidate from phase 1 to phase 3. Dr. Schotzinger began his pharmaceutical career at Abbott Laboratories where he held positions of increasing responsibility, including Director of International Medical Affairs and Vice President of Drug Development. While at Abbott, he gained experience in preclinical and clinical drug development and was involved in the filing and approval of multiple NDAs, SNDAs, ANDAs and INDs.

Dr. Schotzinger received his B.S. in Pharmacy from the Ohio State University. He subsequently earned his Ph.D. degree in pharmacology and medical degree from Case Western Reserve University. He also completed a residency at the University of Virginia, which led to Board Certification in Internal Medicine.

William Moore, Ph.D., Chief Scientific Officer

Dr. Moore has over 23 years of pharmaceutical R&D and management experience. Prior to Viamet, Dr. Moore was Chief Science Officer and Vice President of R&D at Locus Pharmaceuticals, which under his leadership transitioned from a chemistry technology platform company to a development-stage business with multiple corporate partnerships and attainment of significant private equity investment. Previously Dr. Moore was Vice President of Target Discovery & Validation at Axys Pharmaceuticals where he guided the Genomics & Genetics Division in multiple therapeutic areas including cancer target discovery and integrated the group into a multi-site drug development organization. At Arris Pharmaceuticals, Dr. Moore led the molecular biology, protein expression, high through-put screening, genomics, enzymology, and pharmacology groups that discovered and validated a proprietary small molecule zinc metalloenzyme inhibitor technology. Dr. Moore began his pharmaceutical career at Marion Merrell Dow Research Institute where he worked on inhibitors of steroid biosynthetic enzyme.

Dr. Moore received his B.S. in chemistry from Southeastern Massachusetts University. He subsequently earned his Ph.D. degree in chemistry from Brown University and held post-doctoral and faculty appointments in biochemistry at Cornell University Medical College.

Richard Katz, M.D., Chief Business and Financial Officer

Dr. Katz brings over 10 years of pharmaceutical industry experience and 6 years of investment banking experience to Viamet. He has extensive experience in private and public equity financing, strategic alliances, and mergers and acquisitions. Prior to joining Viamet, Dr. Katz was Executive Vice President, Finance and Corporate Development and Chief Financial Officer at Icagen, Inc., a publicly traded biopharmaceutical company. While at Icagen, he led two equity private placements, managed the company's initial public offering, and closed significant strategic alliances with Abbott Laboratories, Johnson & Johnson and Pfizer, which subsequently led to the acquisition of the company by Pfizer.

Dr. Katz received his B.A. in applied mathematics from Harvard University. He subsequently earned his medical degree from Stanford University and M.B.A from Harvard University.

William Hoekstra, Ph.D., Vice President, Medicinal Chemistry

Dr. Hoekstra brings over 25 years of medicinal chemistry experience to Viamet where he has led the implementation of the Metallophile^® Technology. Prior to joining Viamet, Dr. Hoekstra was Associate Director, Discovery Medicinal Chemistry at GlaxoSmithKline where he managed the company's nuclear receptor modulator program which resulted in the identification of several clinical candidates. Prior to GlaxoSmithKline, Dr. Hoekstra was at the R. W. Johnson Pharmaceutical Research Institute where he directed the discovery and lead optimization of numerous new chemical entities, including elarofiban, a clinical-stage antithrombotic, and RWJ-351647, a clinical-stage aquaretic. Dr. Hoekstra began his pharmaceutical career at the Merrell Dow Research Institute.

Dr. Hoekstra received his B.S. from Hope College. He subsequently earned his Ph.D. degree in organic chemistry from Emory University.

Neil Moore, Vice President, Commercial Operations

Mr. Moore brings over 25 years of pharmaceutical and life science experience to Viamet, including multiple start-up companies. His previous experience includes business development roles with Viamet, Norak Biosciences, Inc., Xanthon, Inc., and SARCO, Inc. Mr. Moore's previous experience also includes seed-stage funding for biotechnology companies while at the North Carolina Biotechnology Center and pharmaceutical industry experience with Glaxo, Inc.

Mr. Moore received B.S. degrees in biology and chemistry from the State University of New York, College at Fredonia and earned an M.S. from the University of Oregon and an M.B.A. from Duke University.